

**FORM 51-102F3
MATERIAL CHANGE REPORT**

1. Name and Address of Company:

Aileron Ventures Limited ("**Aileron**")
400, 2424 - 4th Street SW
Calgary, Alberta
T2S 2T4

2. Date of Material Change:

March 31, 2011

3. News Release:

A news release was issued and disseminated on April 1, 2011 through a recognized news service by, or on behalf of, Aileron.

4. Summary of Material Change:

On April 1, 2011, Immunall Science Inc. ("**Immunall**"), Altius Edge Ltd. ("**Altius**"), Aileron and Nautor Progressive Corporation ("**Nautor**") announced that Immunall and Altius completed an amalgamation (the "**Amalgamation**") to form a new company to continue under the name Immunall Science Inc. ("**Amalco**"). The Amalgamation was approved by the shareholders of each of Immunall and Altius at shareholder meetings held on February 15, 2011.

As a result of the Amalgamation, each of Aileron and Nautor have become "reporting issuers" in each of the provinces of British Columbia, Alberta and Ontario.

5. Full Description of Material Change:

Immunall, Altius, Aileron and Nautor announced that Immunall and Altius have completed an amalgamation to form a new company to continue under the name Immunall Science Inc.. The Amalgamation was approved by the shareholders of each of Immunall and Altius at shareholder meetings held on February 15, 2011.

Pursuant to the Amalgamation, the holders of Immunall common shares ("**Immunall Shares**") received, in exchange for each Immunall Share held, one (1) common share of Amalco, 0.025 of a common share of Nautor and 0.025 of a common share of Aileron; also, holders of stock options of Immunall received an equivalent number of stock options of Amalco on substantially the same terms and conditions as the stock options of Immunall currently held. Additionally, each of the former shareholders of Altius (Nautor and Aileron) received, in exchange for each common share of Altius held, one (1) common share of Amalco resulting in each of Nautor and Aileron receiving 1,850,000 common shares of Amalco. Following completion of the Amalgamation, the former holders of Immunall Shares hold, as a group, approximately 91.25% of the issued and outstanding common shares of Amalco and approximately 10% of issued and outstanding common shares of each of Nautor and Aileron. Each of Nautor and Aileron now hold approximately 4.375% of the outstanding common shares of Amalco.

Amalco intends to continue to pursue the former business of Immunall prior to the Amalgamation relating to its patented process for extracting certain components from American Ginseng which

have been shown to strengthen the immune system. The management team of Amalco is comprised of the former management team of Immunall and the board of directors of Amalco is comprised of the former board members of Immunall.

As a result of the Amalgamation, each of Aileron and Nautor have become "reporting issuers" in each of the provinces of British Columbia, Alberta and Ontario. Each of Aileron and Nautor will continue to evaluate businesses and assets with a view to completing an acquisition of a business or assets.

6. Reliance on Subsection 7.1(2) of National Instrument 51-102:

N/A

7. Omitted Information:

N/A

8. Executive Officer:

For further information, please contact:

John Mackay, Director
Telephone: (403) 218-6509
Fax: (403) 266-1541

9. Date of Report:

April 8, 2011